Adolescent Substance Abuse: Progressive Treatment

Substance Abuse Clinical Trial

— ADAPT  

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00680576
• Other study ID #: DA023568
• Secondary ID: R01DA023568
• Status: Completed
• Phase: Phase 1
• First received: May 16, 2008
• Last updated: October 8, 2014
• Start date: March 2008
• Est. completion date: August 2013

Study information

• Verified date: October 2014
• Source: Oregon Research Institute
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out more about how to provide effective further treatment for adolescents who have received six weeks of group therapy for substance-use problems and continue to use drugs. Treatments used in the study include a group therapy (MET/CBT), an individual therapy (CBT), and a family therapy (FFT). The study will look at whether abstinence or a very low level of use is a better guide for deciding whether further treatment is needed, how well different combinations of treatment work to reduce substance use, and whether it is possible to predict in advance which adolescents will respond best to which types of treatment. Study investigators expect that a treatment strategy using what is learned about these issues in the first half of the project to develop an "adaptive" treatment model will work better than a "fixed" treatment to reduce adolescent substance use.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 140
• Est. completion date: August 2013
• Est. primary completion date: August 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 13 Years to 18 Years

Eligibility

Inclusion Criteria:

1. 13 to 18 years if age

2. Meet DSM-IV (APA, 1994) diagnostic criteria for substance abuse or dependence

3. Live in the Albuquerque metropolitan area or surrounding communities

4. Sufficient residential stability to permit probable contact at follow-up (e.g., not homeless at time of intake).

Exclusion Criteria:

1. There is evidence of psychotic or organic state of sufficient severity to interfere with the understanding of study instruments and procedures

2. The adolescent is deemed dangerous to self or others during evaluation

3. Services other than outpatient treatment are required for the adolescent (e.g., inpatient, detoxification)

4. Marijuana use is reported as being less than 13% of days in the previous 90 days.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Substance Abuse
• Substance-Related Disorders

Intervention

Behavioral:
• CBT, Cognitive Behavioral Therapy
Eight weekly sessions of individual Cognitive Behavioral Therapy, to develop skills enabling adolescents stop or reduce their drug use.
• FFT, Family Functional Therapy
Eight weekly sessions of Functional Family Therapy designed to strengthen family relationships and build skills to help the adolescent stop or reduce his/her drug use.

Locations

Country	Name	City	State
United States	Oregon Res. Inst. Center for Family & Adolescent Research (CFAR)	Albuquerque	New Mexico

Sponsors (1)

Lead Sponsor	Collaborator
Oregon Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Urine drug screens		Pretx, 6, 14 and 22 weeks, 3 and 6 months after initial treatment session	No